Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 04    symbols : NTRA    save search
Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer
Published: 2021-08-04 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K twitter stocktwits trandingview |
Health Services
 | | O: 0.13% H: 3.4% C: 3.19%
cancer breast cancer trial diagnostic
Gainers vs Losers
65% 35%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
ILAG | $0.51 6.03% 29.06% 430K twitter stocktwits trandingview |

MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.